Understanding Liquid Biopsy for Cancer Detection

Liquid biopsy is a modern, non-invasive diagnostic method that is gaining prominence in the field of oncology. Unlike traditional tissue biopsies, which require surgically removing a piece of the tumor, a liquid biopsy typically involves taking a simple blood sample. The goal is to detect genetic material or cells shed by the tumor into the bloodstream.

What Does Liquid Biopsy Detect?

Liquid biopsy is based on the detection of circulating components released by the tumor. Several types of components can be present in the blood, including:

• Circulating tumor cells (CTCs): These are whole cancer cells that have detached from the primary tumor or metastatic sites and entered the bloodstream.
• Circulating tumor DNA (ctDNA): This is fragmented DNA released into the bloodstream by dying tumor cells.
• Exosomes and other extracellular vesicles: These can carry proteins, RNA, and DNA from tumor cells.
• Tumor-derived proteins: These are proteins secreted or shed by cancer cells.

The question asks what circulating component is detected by liquid biopsy for cancer detection.

Analyzing the Options

Let's look at the provided options:

• Tumor proteins: While tumor-derived proteins can be present in circulation and are used as biomarkers (like PSA for prostate cancer), liquid biopsy primarily focuses on detecting genetic material (DNA) or intact cells.
• Tumor cells: Circulating tumor cells (CTCs) are indeed detected by some liquid biopsy techniques. Detecting CTCs can provide information about the tumor cells themselves.
• Tumor DNA: Circulating tumor DNA (ctDNA) is fragmented DNA shed by tumor cells. Detecting and analyzing ctDNA is a major focus of many liquid biopsy methods because it carries the genetic mutations characteristic of the tumor. It can be detected even when CTCs are scarce.
• Bone marrow cells: Bone marrow cells are involved in blood formation and are not the primary target for detecting solid tumors via a liquid biopsy of peripheral blood. While cancer can affect bone marrow (like leukemia or metastatic solid tumors), liquid biopsy in the context of detecting "several types of cancer" generally refers to identifying tumor material originating from solid tumors circulating in the blood, not normal bone marrow components.

Focus on Circulating Tumor DNA (ctDNA)

While both circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) are key targets in liquid biopsy for cancer detection, ctDNA is often highlighted as a highly promising and widely studied analyte. Its detection allows for genetic analysis of the tumor without needing a tissue sample, providing insights into mutations, treatment resistance, and disease progression.

Given the options and the common focus in the field, liquid biopsy for detecting several types of cancer heavily relies on finding circulating tumor DNA.